His primary areas of study are Immunology, Interleukin 6, Internal medicine, Cytokine and Gastroenterology. His work on Antibody, Acute-phase protein and Host defence as part of general Immunology study is frequently connected to Allergic airway inflammation, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His Interleukin 6 research is multidisciplinary, incorporating perspectives in Hypergammaglobulinemia, T cell and Pathogenesis, Pathology.
Internal medicine is a component of his Rheumatoid arthritis and Arthritis studies. His Cytokine research incorporates elements of Endocrinology and STAT protein. His Gastroenterology research includes elements of Pharmacokinetics, Placebo and Adverse effect.
His primary scientific interests are in Immunology, Interleukin 6, Internal medicine, Cytokine and Molecular biology. His work in Interleukin 6 addresses issues such as Acute-phase protein, which are connected to fields such as Serum amyloid A. His research investigates the connection between Internal medicine and topics such as Gastroenterology that intersect with problems in Adverse effect.
His research in Cytokine intersects with topics in Chemokine, STAT3 and Tumor necrosis factor alpha. His study on Molecular biology also encompasses disciplines like
His primary areas of investigation include Tocilizumab, Internal medicine, Rheumatoid arthritis, Immunology and Interleukin 6. His studies in Tocilizumab integrate themes in fields like Antibody, Methotrexate and Pharmacology. He has included themes like Inflammation, Proinflammatory cytokine and Tumor necrosis factor alpha in his Rheumatoid arthritis study.
His work carried out in the field of Proinflammatory cytokine brings together such families of science as Endocrinology and Cytokine. His work on Pathogenesis, Arthritis and Hepcidin as part of general Immunology research is often related to Pyrin domain, thus linking different fields of science. Kazuyuki Yoshizaki undertakes multidisciplinary studies into Interleukin 6 and Sarilumab in his work.
Kazuyuki Yoshizaki focuses on Tocilizumab, Immunology, Rheumatoid arthritis, Interleukin 6 and Castleman disease. Internal medicine covers Kazuyuki Yoshizaki research in Tocilizumab. He studies Internal medicine, focusing on Arthritis in particular.
The study incorporates disciplines such as Tumor necrosis factor alpha, Pharmacokinetics, Pharmacodynamics, Methotrexate and Randomized controlled trial in addition to Rheumatoid arthritis. His Interleukin 6 study combines topics from a wide range of disciplines, such as Plasma cell, Hepcidin and Pathogenesis. His research in Castleman disease tackles topics such as Siltuximab which are related to areas like Intensive care medicine, Combination chemotherapy, Erythrocyte sedimentation rate, Hepatosplenomegaly and Plasmacytosis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.
R Atreya;J Mudter;S Finotto;J Müllberg.
Nature Medicine (2000)
Structure and function of a new STAT-induced STAT inhibitor
Tetsuji Naka;Masashi Narazaki;Moritoshi Hirata;Tomoshige Matsumoto.
Treatment of rheumatoid arthritis with humanized anti–interleukin-6 receptor antibody: A multicenter, double-blind, placebo-controlled trial
Norihiro Nishimoto;Kazuyuki Yoshizaki;Nobuyuki Miyasaka;Kazuhiko Yamamoto.
Arthritis & Rheumatism (2004)
Pathogenic Significance of Interleukin-6 (IL-6/BSF-2) in Castleman's Disease
K Yoshizaki;T Matsuda;N Nishimoto;T Kuritani.
Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Norihiro Nishimoto;Yuzuru Kanakura;Katsuyuki Aozasa;Takeshi Johkoh.
A pilot randomized Trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease
Hiroaki Ito;Masakazu Takazoe;Yoshihiro Fukuda;Toshifumi Hibi.
TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling
Christoph Becker;Massimo C. Fantini;Christoph Schramm;Hans A. Lehr.
Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double‐blind, placebo‐controlled, dose‐escalation trial
Ernest Choy;D A Isenberg;Toby Garrood;S Farrow.
Arthritis & Rheumatism (2002)
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.
Norihiro Nishimoto;Norihiro Nishimoto;Mitsuko Sasai;Mitsuko Sasai;Yoshihito Shima;Yoshihito Shima;Masashi Nakagawa;Masashi Nakagawa.
IL-6 Is Required for the Development of Th1 Cell-Mediated Murine Colitis
Mitsunari Yamamoto;Kazuyuki Yoshizaki;Tadamitsu Kishimoto;Hiroaki Ito.
Journal of Immunology (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: